My group’s research revolves around recombinant protein technology and the ways it can enable drug discovery both at early exploratory and late “near clinic” stages. In the early stages of research, this includes, for example, target validation exercises, recombinant target generation for functional screening or for use as immunogen, binding studies, biochemical enzyme assays or cellular assays.

As programs progress, candidate therapeutic proteins are produced and characterized, possible manufacturing liabilities are addressed, and relevant analogues from appropriate tox species might be studied for equivalency. Our work includes molecular biology, protein expression, generation of cellular assays, protein purification and characterization and some limited biophysical studies. We collaborate with biologists across the research department as well as the larger biochemistry group, the high-throughput assay group, the structural biologists and the chemists. We work with both biologics programs as well as small molecule programs. While the biology is, of course, ever-expanding, we are also always looking to develop novel tools and workflows that enable capacity or capability increases.


  • Postdoctoral, Laboratory of Michael L. Dustin, NYU School of Medicine, New York, NY, 2008
  • Ph.D., Laboratory of Lawrence J. Stern, Massachusetts Institute of Technology, Cambridge, MA, 2002

Selected Publications

See more scientists